Clinical Trial Update: Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of Troxatyl given by continuous infusion in subjects with refractory acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Troxatyl

Snippet

Sponsor: SGX Pharmaceuticals, Inc. | Conditions: Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: TERMINATED